Q3 Earnings Forecast for Pharvaris Issued By HC Wainwright

Pharvaris N.V. (NASDAQ:PHVS) – Analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for shares of Pharvaris in a research report issued to clients and investors on Wednesday, October 15th. HC Wainwright analyst P. Trucchio forecasts that the company will post earnings per share of ($0.69) for the quarter. HC Wainwright has a “Buy” rating and a $60.00 price target on the stock. The consensus estimate for Pharvaris’ current full-year earnings is ($2.71) per share. HC Wainwright also issued estimates for Pharvaris’ Q4 2025 earnings at ($0.71) EPS, FY2025 earnings at ($3.31) EPS, Q1 2026 earnings at ($0.80) EPS, Q2 2026 earnings at ($0.83) EPS, Q3 2026 earnings at ($0.87) EPS, Q4 2026 earnings at ($0.91) EPS, FY2026 earnings at ($3.42) EPS, FY2027 earnings at ($2.67) EPS, FY2028 earnings at ($0.72) EPS and FY2029 earnings at $2.22 EPS.

PHVS has been the topic of several other research reports. Bank of America raised Pharvaris from an “underperform” rating to a “neutral” rating and lifted their price target for the company from $16.00 to $27.00 in a research note on Thursday, October 9th. Zacks Research raised Pharvaris from a “strong sell” rating to a “hold” rating in a research note on Monday, August 18th. Weiss Ratings reissued a “sell (d-)” rating on shares of Pharvaris in a research note on Wednesday, October 8th. Finally, JMP Securities dropped their price target on Pharvaris from $55.00 to $52.00 and set a “market outperform” rating on the stock in a research note on Wednesday, August 13th. Five investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $37.17.

Pharvaris Price Performance

PHVS opened at $21.86 on Friday. The business’s 50-day moving average price is $23.01 and its two-hundred day moving average price is $19.31. Pharvaris has a 1 year low of $11.51 and a 1 year high of $26.33. The company has a market capitalization of $1.14 billion, a price-to-earnings ratio of -6.51 and a beta of -2.77.

Pharvaris (NASDAQ:PHVS) last issued its quarterly earnings data on Tuesday, August 12th. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.87) by ($0.07).

Hedge Funds Weigh In On Pharvaris

Several hedge funds have recently modified their holdings of the stock. TFG Asset Management GP Ltd grew its holdings in shares of Pharvaris by 48.1% in the 2nd quarter. TFG Asset Management GP Ltd now owns 188,100 shares of the company’s stock valued at $3,311,000 after acquiring an additional 61,105 shares in the last quarter. TD Asset Management Inc grew its holdings in shares of Pharvaris by 27.4% in the 2nd quarter. TD Asset Management Inc now owns 99,510 shares of the company’s stock valued at $1,751,000 after acquiring an additional 21,388 shares in the last quarter. Geode Capital Management LLC grew its holdings in shares of Pharvaris by 41.1% in the 2nd quarter. Geode Capital Management LLC now owns 54,102 shares of the company’s stock valued at $952,000 after acquiring an additional 15,769 shares in the last quarter. The Manufacturers Life Insurance Company grew its holdings in shares of Pharvaris by 19.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 48,857 shares of the company’s stock valued at $860,000 after acquiring an additional 7,879 shares in the last quarter. Finally, Deutsche Bank AG grew its holdings in Pharvaris by 55.1% during the first quarter. Deutsche Bank AG now owns 28,174 shares of the company’s stock worth $442,000 after purchasing an additional 10,006 shares during the period.

About Pharvaris

Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial.